83 related articles for article (PubMed ID: 5120302)
21. High-dose melphalan (200 mg/m2) supported by autologous stem cell transplantation is safe and effective in elderly (>or=65 years) myeloma patients: comparison with younger patients treated on the same protocol.
Jantunen E; Kuittinen T; Penttilä K; Lehtonen P; Mahlamäki E; Nousiainen T
Bone Marrow Transplant; 2006 May; 37(10):917-22. PubMed ID: 16670701
[TBL] [Abstract][Full Text] [Related]
22. Possible role of the immune response in the stem cell depression produced by melphalan.
Dunn CR
J Natl Cancer Inst; 1974 Jan; 52(1):181-8. PubMed ID: 4810961
[No Abstract] [Full Text] [Related]
23. Expression of c-Kit isoforms in multiple myeloma: differences in signaling and drug sensitivity.
Montero JC; López-Pérez R; San Miguel JF; Pandiella A
Haematologica; 2008 Jun; 93(6):851-9. PubMed ID: 18443272
[TBL] [Abstract][Full Text] [Related]
24. Peripheral blood progenitors mobilised by G-CSF (filgrastim) and reinfused as unprocessed autologous whole blood shorten the pancytopenic period following high-dose melphalan in multiple myeloma.
Ossenkoppele GJ; Jonkhoff AR; Huijgens PC; Nauta JJ; van der Hem KG; Dräger AM; Langenhuijsen MM
Bone Marrow Transplant; 1994 Jan; 13(1):37-41. PubMed ID: 7517255
[TBL] [Abstract][Full Text] [Related]
25. Gentamicin reduces the self-renewal capacity of murine pluripotent hemopoietic stem cells.
Kerk DK; Myers CP; Hays EF
Exp Hematol; 1983 Oct; 11(9):819-27. PubMed ID: 6357826
[TBL] [Abstract][Full Text] [Related]
26. Effect of chemotherapy with alkylating agents on the yield of CD34+ cells in patients with multiple myeloma. Results of the Spanish Myeloma Group (GEM) Study.
de la Rubia J; Bladé J; Lahuerta JJ; Ribera JM; Martínez R; Alegre A; García-Laraña J; Fernández P; Sureda A; de Arriba F; Carrera D; Besalduch J; García Boyero R; Palomera Bernal L; Hernández MT; García PR; Pérez-Calvo J; Alcalá A; Casado LF; San Miguel J
Haematologica; 2006 May; 91(5):621-7. PubMed ID: 16627253
[TBL] [Abstract][Full Text] [Related]
27. Melphalan and dexamethasone for patients with multiple myeloma who are not candidates for autologous stem cell transplantation.
Sharma A; Lokeshwar N; Raina V; Mohanti BK; Kumar R
Natl Med J India; 2007; 20(3):121-4. PubMed ID: 17867615
[TBL] [Abstract][Full Text] [Related]
28. Colony formation in agar by adult bone marrow multipotential hemopoietic cells.
Johnson GR
J Cell Physiol; 1980 Jun; 103(3):371-83. PubMed ID: 7400223
[TBL] [Abstract][Full Text] [Related]
29. The development of a system for study of bone marrow transplantation in vitro: effects of X-irradiation dose rate and chemotherapeutic agents on the isolated bone marrow microenvironment.
Greenberger JS; Cohen GI; Sakakeeny MA
Kroc Found Ser; 1984; 18():195-209. PubMed ID: 6442345
[No Abstract] [Full Text] [Related]
30. Melphalan and its role in the management of patients with multiple myeloma.
Falco P; Bringhen S; Avonto I; Gay F; Morabito F; Boccadoro M; Palumbo A
Expert Rev Anticancer Ther; 2007 Jul; 7(7):945-57. PubMed ID: 17627453
[TBL] [Abstract][Full Text] [Related]
31. [High-dose melphalan in patients with multiple myeloma].
Moreau P; Le Bonniec M; Harousseau JL
Bull Cancer; 1999 Mar; 86(3):283-8. PubMed ID: 10210762
[TBL] [Abstract][Full Text] [Related]
32. [Behaviour of bone marrow and splenic hemopoietic stem cells following administration of anthracyclines].
Massa G; Bogliolo G; Ghio R; Muzzulini C; D'Amore F
Boll Soc Ital Biol Sper; 1981 Jun; 57(12):1311-5. PubMed ID: 6945864
[TBL] [Abstract][Full Text] [Related]
33. Factors affecting the proliferation and differentiation of clonogenic hematopoietic stem cells in vitro.
Monette FC; Sigounas G
Blood Cells; 1984; 10(2-3):261-86. PubMed ID: 6085720
[TBL] [Abstract][Full Text] [Related]
34. The regulation of hemopoietic cell development by the stromal cell environment and diffusible regulatory molecules.
Dexter TM; Simmons P; Purnell RA; Spooncer E; Schofield R
Prog Clin Biol Res; 1984; 148():13-33. PubMed ID: 6379657
[No Abstract] [Full Text] [Related]
35. Effect of pentoxifylline, a multidrug resistance reversal agent, on haemopoietic stem cell homing.
Gude RP; Chitnis MP; Rao SG
Cell Biol Int; 1994 Feb; 18(2):79-84. PubMed ID: 8019484
[TBL] [Abstract][Full Text] [Related]
36. [Mobilization of circulating hematopoietic stem cells by granulocyte colony stimulating factor after chemotherapy in multiple myeloma].
Ohler L; Scholten C; Reiter E; Tiefengraber E; Jäger U; Strobl H; Lechner K; Höcker P; Geissler K
Wien Klin Wochenschr; 1993; 105(20):580-4. PubMed ID: 7505076
[TBL] [Abstract][Full Text] [Related]
37. Chemotherapy of multiple myeloma: melphalan--40 years old and still going strong.
Bergsagel PL
Biol Blood Marrow Transplant; 2003 Jan; 9(1):2-3. PubMed ID: 12533738
[No Abstract] [Full Text] [Related]
38. Stimulation of the proliferation of hemopoietic stem cells in irradiated bone marrow cell culture.
Mori KJ; Izumi H; Seto A
Biomedicine; 1981 Mar; 35(1):16-8. PubMed ID: 7236842
[TBL] [Abstract][Full Text] [Related]
39. Interactions of cytotoxic and anti-inflammatory agents on normal and neoplastic tissue.
Powles TJ; Frank GJ; Millar JL
Adv Prostaglandin Thromboxane Res; 1980; 6():587-9. PubMed ID: 7386294
[No Abstract] [Full Text] [Related]
40. Haemopoietic multipotential stem cells in culture.
Johnson GR
Clin Haematol; 1984 Jun; 13(2):309-27. PubMed ID: 6380851
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
